Thr218
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr218  -  PKCD (human)

Site Information
TAANSRDtIFQkERF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 7445829

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 4 , 6 , 7 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , lung cancer ( 6 , 7 ) , non-small cell lung cancer ( 6 , 7 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
PKCD (human) ( 5 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

4

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

5

Rybin VO, et al. (2009) Regulatory autophosphorylation sites on protein kinase C-delta at threonine-141 and threonine-295. Biochemistry 48, 4642-51
19366211   Curated Info

6

Possemato A (2009) CST Curation Set: 6455; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

7

Possemato A (2009) CST Curation Set: 6437; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/control; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info